HRTS

$HRTS chatter on StockTwits

• 
  Makingmillions192@Makingmillions192BullishJul 14

  $OZEM $THNR $HRTS While Big Pharma races to acquire oral GLP-1 delivery tech, this platform developer is about to drop human and next-gen animal datasets that could rewrite the market's tolerability standards. The Late-Summer Data Drop Schedule: Lexaria Bioscience: NASDAQ: LEXX Mid-August 2026 | Animal Study #2 (GLP-1-A26-2) Pharma is watching platform compatibility and PK data for tomorrow's next-gen blockbusters: Eli Lilly's retatrutide and Novo Nordisk's amycretin. Late August / Early September 2026 | Human Study #7 (GLP-1-H26-7) THE MAIN EVENT. Head-to-head 5-week steady-state human data comparing DehydraTECH-semaglutide tablets directly against Wegovy. Pharma is tracking bio-absorption and a projected ~40% reduction in GI side effects. Early September 2026 | Animal Study #1 (GLP-1-A26-1) Pharma is watching alternative novel formulations designed to bypass or improve upon traditional, erratic SNAC-inclusive carriers.

  View on StockTwits ↗
• 
  Stocktwits News@StocktwitsNewsJun 5

  Why Did BCDA Stock Surge More Than 50% Today? $BCDA $HRTS https://stocktwits.com/news/equity/markets/why-did-bcda-stock-surge-more-than-50-today/cZ0FYVtReCj

  View on StockTwits ↗
• 
  Billioner@BillionerOfKingFeb 22

  $HRTS Current Stock Price: $35.87 Contracts to trade: $30.0 HRTS Mar 20 2026 Call Entry: $1.45 Exit: $2.79 ROI: 92% Hold ~31 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts

  View on StockTwits ↗
• 
  Billioner@BillionerOfKingDec 30

  $HRTS Current Stock Price: $35.49 Contracts to trade: $30 HRTS Mar 20 2026 Call Entry: $1.45 Exit: $1.84 ROI: 27% Hold ~22 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts

  View on StockTwits ↗
• 
  Monica Gonzalez@TransactionTutorDec 26

  $HRTS Macro trends are relevant, yet internal execution remains the decisive catalyst. Margins must remain resilient as activity scales. Guidance slippage would be magnified by the market. Future returns will be dictated by execution quality, not headlines.

  View on StockTwits ↗
• 
  Billioner@BillionerOfKingNov 13

  $HRTS Current Stock Price: $34.32 Contracts to trade: $30 HRTS Mar 20 2026 Call Entry: $1.45 Exit: $2.87 ROI: 98% Hold ~26 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts

  View on StockTwits ↗
• 
  Benzinga@benzingaSep 25

  EXCLUSIVE: Novo Nordisk Faces Political Heat Over Weight-Loss Drug Prices Ahead Of Elections, Yet 'The Real Issue Is With The Middlemen' $HRTS $NVO https://www.benzinga.com/analyst-ratings/analyst-color/24/09/41025381/exclusive-novo-nordisk-faces-political-heat-over-weight-loss-drug-prices-ahead-of-e

  View on StockTwits ↗
• 
  Goku@SonGokuAug 6

  Added to my watchlist going to keep an eye on this one, thanks for shouting this out !! $HRTS

  View on StockTwits ↗
• 
  Goku@SonGokuAug 6

  Just came across this ticker $HRTS

  View on StockTwits ↗
• 
  Comiendomierda@ComiendomierdaBullishJul 8

  $HRTS Just read the Benzinga article, I had no idea of this ETF’s existence prior. Lotsa fatsos around, I think GLP-1 is here to stay.

  View on StockTwits ↗
• 
  Howard Lindzon@howardlindzonJun 25

  $HRTS etf Is cool...for obesity and heart

  View on StockTwits ↗
• 
  Ro Patel@Ro_PatelJun 17

  Analyst raising annual global sales forecasts for obesity treatments to about $150B by the early 2030s vs top sales ests were in the $100B range a year ago. Analysts cite recent data showing the self-injected drugs help stave off costly emergencies like heart attack and stroke or treat chronic conditions like sleep apnea, supporting the case for employers and insurers to pay for them. Global spending on obesity medications totaled $24B last year That +27% annual growth estimate compares with a prior projection of +13%. Supplies of both $NVS Wegovy & $LLY Zepbound remain constrained, but the companies have been increasing production. In the US 40% of adults are obese & another 30% are overweight. Worldwide adult obesity rate has more than doubled since 1990 - over a billion people globally. Over 80 experimental obesity drugs have reached the human testing stage but the bull case is that access will widen & higher volume will offset price erosion. $VKTX $AMGN $HRTS

  View on StockTwits ↗
• 
  William Meyers@basscat12BullishJun 6

  $ATYR $HRTS New Options Listings courtesy @marketchameleonwins

  View on StockTwits ↗
• 
  Zacks.com@ZacksResearchJun 4

  Two dominant investing themes over the past year have been AI and weight-loss drugs. Neena Mishra focuses on weight loss ETFs. $HRTS https://www.zacks.com/stock/news/2283455/etfs-to-profit-from-the-weight-loss-drug-boom

  View on StockTwits ↗
• 
  Jane Edmondson@VettaJaneMay 24

  $THNR $OZEM $HRTS $LLY $NVO The $THNR Weight Loss ETF has won the performance battle in its first week out. 🏆

  View on StockTwits ↗

Recent $TICKER stream from stocktwits.com — refreshed every 5 minutes. Sentiment tags are self-reported by posters. Not investment advice.